Core Insights - Kane Biotech presented new clinical and scientific data at the Innovations in Wound Healing Annual Meeting, emphasizing its commitment to addressing complex health conditions [1][2] - The company showcased its FDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and Spray, highlighting their role in improving patient outcomes [4][5] Company Developments - Kane Biotech shared case study data demonstrating improved healing trajectories in chronic wounds using its advanced wound gel platform [5] - New findings were presented regarding the effectiveness of Kane's wound gel technology in treating Chronic Radiation-Induced Achilles Ulcer, where conventional therapies often fail [5] - Data on Hidradenitis Suppurativa (HS) illustrated the potential of revyve to reduce infection burden and improve outcomes in this condition [5] Market Insights - The presentations reflected how Kane's innovations are being integrated into care pathways, delivering measurable value to health systems [5] - The company is focused on developing novel wound care treatments that disrupt biofilms, which contribute to antibiotic resistance and serious clinical outcomes [6]

WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Health Canada has approved its revyve® Antimicrobial Wound Gel Spray for use in Canada. Health Canada approved revyve Antimicrobial Wound Gel Spray revyve Antimicrobial Wound Gel Spray has been previously cleared under the FDA 510(k) process. This Health Canada approval represents another regulatory milestone for Kane and the Company’s commitment to advancing wo ...

WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results. Third Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended September 30, 2025 was $8,499 compared to $1,282,698 in the three months ended September 30, 2024. The vast majority of revenue recorded in the comparative quarter was relat ...

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 16 million common shares (“Shares”) at a price of $0.05 per Share for gross proceeds of up to $800,000. The net proceeds of the Offering will be used for working capital and general corpora ...

Core Insights - Kane Biotech Inc. announced new clinical and pre-clinical data showcasing the effectiveness of its FDA-cleared revyve Antimicrobial Wound Gel and revyve Wound Gel Spray in diabetic foot ulcer healing and burn wound infection control [1] Clinical Data: Outperforming the Standard of Care - At the Diabetic Foot Conference 2025, data presented indicated that revyve achieved healing outcomes surpassing the current standard of care for diabetic foot ulcers, with an average percent area reduction (PAR) of 97% in 4 weeks compared to the 40-50% benchmark [2][7] - Complete wound closure was achieved in all cases within 8-12 weeks across a multi-center series [7] - The gel effectively managed bacterial loads, aiding patients with conditions such as Peripheral Arterial Disease and elevated A1c levels [3] Rapid Antimicrobial Efficacy in Burn Care - At the Southern Region Burn Conference, pre-clinical data showed a 99.99% to 99.9999% reduction in burn-associated pathogens within 30 minutes of application, with sustained antibiofilm activity for a minimum of 7 days [4][8] - The product's ability to achieve up to a six-log reduction in microbial load within minutes represents a significant advancement in burn wound management [8] Company Strategy and Future Outlook - These findings are part of Kane's three-pillar strategy aimed at significantly impacting wound care in the United States, emphasizing the potential of revyve's antibiofilm and antimicrobial technology to transform wound healing outcomes [8] - Kane Biotech is focused on developing novel wound care treatments that disrupt biofilms, which are major contributors to antibiotic resistance in wounds [11]

Core Insights - Kane Biotech Inc. has completed a U.S. FDA 510(k) clearance submission for its revyve Antimicrobial Wound Cleanser, marking a significant step in its product development [1][2] Product Development - The revyve Antimicrobial Wound Cleanser is the third product in the revyve line, complementing the existing revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray [2] - This new product aims to enhance routine wound management by providing irrigation to cleanse both acute and chronic wounds, thereby reducing bacterial load and removing debris [2] Market Opportunity - The annual U.S. market size for wound cleansers surpassed $200 million USD in 2024, indicating a substantial market opportunity for Kane Biotech's new product [3]

Core Insights - Kane Biotech Inc. has successfully enrolled 28 participants in its revyve Antimicrobial Wound Gel and Spray U.S. Case Series Studies, surpassing the initial target of 25 participants [1] - The company’s products, including the revyve Antimicrobial Wound Gel and Spray, have received U.S. FDA 510(k) clearance, indicating regulatory approval for their use [3][4] - Data from the clinical series is expected to be presented at various medical meetings in 2025 and 2026, highlighting the growing interest from clinicians and patients [4] Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which are significant contributors to antibiotic resistance in wounds [4] - The company aims to improve healing outcomes for patients suffering from challenging wounds and burns through its revyve product line [4] - The revyve products are designed to address both biofilms and wound bacteria, potentially transforming the treatment landscape for wound care [4]

Core Insights - Kane Biotech Inc. is presenting clinical data on wound healing at the SAWC Fall conference, showcasing the effectiveness of their revyve Antimicrobial Wound Gel in treating complex wounds over two years old [1][4]. Group 1: Clinical Data Presentation - The first presentation discusses the clinical use of revyve Antimicrobial Wound Gel on a two-year-old non-healing Stage 4 sacral ulcer, resulting in pain reduction from 10/10 to 0 and a decrease in wound size over three weeks [2]. - The second presentation highlights the use of revyve Antimicrobial Wound Gel combined with vibrational debridement on a non-healing venous leg ulcer, achieving a 60% reduction in wound size over eight weeks and pain levels decreasing from 5/10 to 0 [3]. Group 2: Product Information - Kane Biotech's revyve Antimicrobial Wound Gel and Wound Gel Spray have received FDA 510(k) clearance and will be exhibited at the conference, with the Interim CEO meeting potential US distributors [4][6]. - The revyve products are designed to disrupt biofilms and improve healing outcomes, addressing antibiotic resistance in wounds, and are also approved by Health Canada [7].

Financial Performance - Total revenue for Q2 2025 was $27,997, a significant decrease from $620,437 in Q2 2024, primarily due to the sale of the animal health business [9] - Gross loss for Q2 2025 was $(45,526), compared to a gross profit of $360,490 in Q2 2024 [9] - Total operating expenses for Q2 2025 were $229,930, down from $1,463,397 in Q2 2024, attributed to staff reductions and other cost-saving measures [9] - Net loss for Q2 2025 was $(348,541), an improvement from a net loss of $(1,215,996) in Q2 2024 [9] Corporate Governance - Three new directors were elected at the Annual and Special Meeting of Shareholders on June 25, 2025, alongside the reelection of three existing directors [2] - Mr. Shameze Rampertab was appointed as Chair of the Audit and Compensation Committee, and Ms. Anne Greven as Chair of the Governance & Nomination Committee [3] Product Development and Clinical Engagement - Kane Biotech presented novel preclinical data and clinical observations at two major North American wound care conferences in 2025 [4] - The company is engaging with key wound care specialists in the U.S. and is completing a clinical case series program to generate additional clinical data [5] Distribution and Financial Obligations - The company terminated its exclusive distribution agreement with ProgenaCare due to material breaches and is in discussions with potential new distributors [6] - Kane Biotech received a notice of default from Prairies Economic Development Canada regarding approximately $1.4 million outstanding from a $2.5 million Contribution Agreement [8] Strategic Outlook - The company aims to enhance its distributor networks in the U.S. and is focused on generating compelling clinical evidence to support the commercialization of its revyve portfolio [10] - The addition of three qualified directors is expected to strengthen the company's strategic capabilities during a pivotal growth stage [10]

Core Viewpoint - Kane Biotech Inc. is undergoing a reorganization phase, which includes terminating its distribution agreement with ProgenaCare and addressing financial obligations with PrairiesCan while advancing its clinical plans for product introduction in the U.S. market [1][2][6]. Group 1: Distribution and Financial Agreements - The company has terminated its exclusive distribution agreement with ProgenaCare due to material breaches [1]. - Kane Biotech received a notice of default from PrairiesCan regarding a Contribution Agreement, which involved repayable contributions totaling $2,491,266, with repayments starting on April 1, 2023 [2]. - The company has made all required repayments except for the payment due on June 1, 2025, and is in communication with PrairiesCan to restructure the remaining loan repayments [2][3]. Group 2: Financing and Related Transactions - An insider provided an unsecured demand loan of $1 million, which will be converted into a five-year, unsecured convertible debenture, subject to TSX Venture Exchange approval [4]. - The debenture will accrue interest at 3% per annum and is convertible into common shares at a price of $0.10 per share [4]. - The conversion of the loan to the debenture is classified as a related party transaction, exempting the company from formal valuation and minority approval requirements [5]. Group 3: Clinical Development - The company is executing its clinical plan for the commercial introduction of its revyve Antimicrobial Wound Gel and Spray in the U.S. market [6]. - Clinical case series are being conducted with medical professionals in chronic wound care and burn care, with data expected to be presented in late 2025 and 2026 [6]. Group 4: Company Overview - Kane Biotech is focused on developing novel wound care treatments that target biofilms, which contribute to antibiotic resistance and adverse clinical outcomes [8].